Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes
Maria O Levitin,Lettie E Rawlins,Gabriela Sanchez-Andrade,Osama A Arshad,Stephan C Collins,Stephen J Sawiak,Phillip H Iffland 2nd,Malin H L Andersson,Caleb Bupp,Emma L Cambridge,Eve L Coomber,Ian Ellis,Johanna C Herkert,Holly Ironfield,Logan Jory,Perrine F Kretz,Sarina G Kant,Alexandra Neaverson,Esther Nibbeling,Christine Rowley,Emily Relton,Mark Sanderson,Ethan M Scott,Helen Stewart,Andrew Y Shuen,John Schreiber,Liz Tuck,James Tonks,Thorkild Terkelsen,Conny van Ravenswaaij-Arts,Pradeep Vasudevan,Olivia Wenger,Michael Wright,Andrew Day,Adam Hunter,Minal Patel,Christopher J Lelliott,Peter B Crino,Binnaz Yalcin,Andrew H Crosby,Emma L Baple,Darren W Logan,Matthew E Hurles,Sebastian S Gerety
DOI: https://doi.org/10.1093/brain/awad231
IF: 14.5
2023-11-02
Brain
Abstract:KPTN-related disorder is an autosomal recessive disorder associated with germline variants in KPTN (previously known as kaptin), a component of the mTOR regulatory complex KICSTOR. To gain further insights into the pathogenesis of KPTN-related disorder, we analysed mouse knockout and human stem cell KPTN loss-of-function models. Kptn -/- mice display many of the key KPTN-related disorder phenotypes, including brain overgrowth, behavioural abnormalities, and cognitive deficits. By assessment of affected individuals, we have identified widespread cognitive deficits (n = 6) and postnatal onset of brain overgrowth (n = 19). By analysing head size data from their parents (n = 24), we have identified a previously unrecognized KPTN dosage-sensitivity, resulting in increased head circumference in heterozygous carriers of pathogenic KPTN variants. Molecular and structural analysis of Kptn-/- mice revealed pathological changes, including differences in brain size, shape and cell numbers primarily due to abnormal postnatal brain development. Both the mouse and differentiated induced pluripotent stem cell models of the disorder display transcriptional and biochemical evidence for altered mTOR pathway signalling, supporting the role of KPTN in regulating mTORC1. By treatment in our KPTN mouse model, we found that the increased mTOR signalling downstream of KPTN is rapamycin sensitive, highlighting possible therapeutic avenues with currently available mTOR inhibitors. These findings place KPTN-related disorder in the broader group of mTORC1-related disorders affecting brain structure, cognitive function and network integrity.